Co-occurring Genomic Alterations Define Major Subsets of <i>KRAS</i> -Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities

2015898 citationsJournal Articlebronze Open Access

Authors

Ferdinandos Skoulidis · The University of Texas MD Anderson Cancer Center

Lauren A. Byers · The University of Texas MD Anderson Cancer Center

Lixia Diao · The University of Texas MD Anderson Cancer Center

Vassiliki A. Papadimitrakopoulou · The University of Texas MD Anderson Cancer Center

Pan Tong · The University of Texas MD Anderson Cancer Center

Julie Izzo · The University of Texas MD Anderson Cancer Center

Abstract

Co-occurring genetic alterations in STK11/LKB1, TP53, and CDKN2A/B-the latter coupled with low TTF1 expression-define three major subgroups of KRAS-mutant lung adenocarcinoma with distinct biology, patterns of immune-system engagement, and therapeutic vulnerabilities.

Topics & Keywords

RNA modifications and cancer Peptidase Inhibition and Analysis Lung Cancer Treatments and Mutations

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Cancer Discovery

Volume 5, Issue 8, pp. 860-877

DOI: 10.1158/2159-8290.cd-14-1236

Field-Weighted Citation Impact: 28.23